Nutra Pharma Corp (NPHC) EBITDA Margin (2010 - 2026)

Nutra Pharma has disclosed EBITDA Margin across 17 years of filings, most recently posting 1263.57% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 91988.0% year-over-year to 1263.57%; the TTM figure through Jun 2026 stood at 1017.76% (down 69941.0% YoY), while the FY2025 annual figure was 567.65%, down 21102.0% from the prior year.
• EBITDA Margin came in at 1263.57% for Q2 2026 at Nutra Pharma, up from 1391.94% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 218.47% in Q4 2024 to a low of 2241.62% in Q1 2022.
• Average EBITDA Margin over 5 years is 814.37%, with a median of 619.08% recorded in 2023.
• Year-over-year, EBITDA Margin jumped 169861 bps in 2022 and plunged 139570 bps in 2025.
• Over 5 years, EBITDA Margin stood at 1293.11% in 2022, then surged by 77 bps to 298.14% in 2023, then gained by 27 bps to 218.47% in 2024, then plunged by 639 bps to 1614.17% in 2025, then rose by 22 bps to 1263.57% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 1263.57% in Q2 2026, 1391.94% in Q1 2026, and 1614.17% in Q4 2025.